PBP2a (MRSA Penicillin-Binding Protein)
Olivia Gumz '27 and Colin Williams '27

Contents:

I. Introduction

Methicillin resistant Staphylococcus aureus (MRSA) derives its notable resistance to β-lactam antibiotics predominantly from the expression of penicillin binding protein 2a (PBP2a), a specialized transpeptidase that sustains cell wall biosynthesis even when endogenous PBPs are inhibited1,4. In the majority of bacterial species, β-lactam antibiotics exert their antibacterial effect by forming a covalent bond with a critical active site serine residue in PBPs, thereby inhibiting peptidoglycan cross linking and ultimately leading to cellular lysis2. The expression of PBP2a circumvents this inhibitory mechanism, enabling MRSA to maintain the structural integrity of its peptidoglycan sacculus and thereby fostering persistent, recalcitrant infections in both nosocomial and community environments.

Even in the presence of β-lactams at inhibitory doses, PBP2a maintains cell-wall integrity in S. aureus by accelerating the final crosslinking steps of peptidoglycan formation4,5. In spite of antibiotic pressure, the enzyme interacts with elongated stem peptides during transpeptidation to create a temporary acyl-enzyme intermediate3. The way the protein modifies its conformational landscape—only substrates that resemble native peptidoglycan activate the tiny, cooperative alterations necessary for efficient catalysis—is what makes PBP2a so powerful, in addition to the chemistry at its catalytic serine3. β-lactams, which usually take over PBPs by imitating D-Ala–D-Ala, bind weakly because they are unable to cause these movements. This functional selectivity explains how MRSA maintains strong cell-wall synthesis and emphasizes the need for effective drug design to take advantage of the enzyme's distinctive conformational gating rather than just focusing on its catalytic core1,5.

II. General Structure

The two primary functional domains of PBP2a are the C-terminal transpeptidase (TP) domain and the N-terminal allosteric domain These domains are joined by interdomain strands and loops that enable long-range structural communication over approximately 60 Å of the protein1,5. The regulatory binding pocket, which detects peptidoglycan fragments and initiates the opening of the catalytic groove, is located in the allosteric domain, which is primarily made up of β-sheet components supported by α-helices5. The catalytic is located at the foot of a long, narrow in the TP domain, which also contains the conserved that characterize PBP transpeptidases1,4. In order to establish the ideal electrostatic environment for D-Ala–D-Ala recognition during catalysis, a number of extended loop regions partially cover this cleft in the resting state and undergo rearrangement1. When combined, these structural characteristics allow PBP2a to carry out peptidoglycan crosslinking while preserving the allosterically gated conformation responsible for MRSA β-lactam resistance.

Catalytic Cleft Panel

III. Peptidoglycan Binding

PBP2a catalyzes the DD-transpeptidation process, which produces the essential cross-links in S. aureus peptidoglycan. The center of the active site is the conserved catalytic serine (Ser403) which is situated within the SXXK motif characteristic of class B PBPs1. The active location is situated at the bottom of a long, narrow groove that, when at rest, is partially protected by prolonged loop areas that limit access1. These structural characteristics explain why PBP2a may effectively bind its natural peptidoglycan substrate despite having a poor basal affinity for β-lactam antibiotics.

The identification of the stem peptide's D-Ala–D-Ala terminus initiates peptidoglycan binding. A short-lived acyl-enzyme intermediate is produced when the catalytic serine attacks the scissile amide link nucleophilically4. Through hydrogen bonding and substrate placement, a number of neighboring residues, such as Lys, Gly, and flexible loop residues around the SXXK motif, aid in stabilizing this intermediate1. For the stem peptide to remain correctly oriented for the ensuing transpeptidation phase, these interactions are crucial.

When the N-terminal allosteric domain is activated, PBP2a experiences conformational changes that improve accessibility even though the active site is typically "closed." The catalytic groove is opened and structural changes are propagated throughout the protein (~60 Å) by binding events at the allosteric location1. Because most β-lactams are too rigid to fit through the small pocket, this conformational coupling permits peptidoglycan substrates to access the active site1,5.

The general layout of PBP2a also supports peptidoglycan binding. In order to stabilize the tetrahedral intermediate during catalysis, loop rearrangements surrounding Ser403 produce a more advantageous electrostatic environment 1. PBP2a's capacity to complement native PBP2 is eliminated by mutations that interfere with these loops or the active-site serine, indicating the crucial function of this catalytic machinery in cell-wall formation4.

While β-lactams, with their bulkier ring structures, are sterically rejected unless the protein has been allosterically activated, peptidoglycan precursors can bind to PBP2a efficiently because they are flexible and can induce the required active-site opening5. A crucial part of MRSA's β-lactam resistance mechanism is this structural differentiation.

V. MRSA and B-lactam Antibiotics

The difficulty of treating MRSA with conventional β-lactam antibiotics can be explained by the structural characteristics of PBP2a1. The majority of β-lactams never form the inhibitory acyl-enzyme complex that inhibits other PBPs because the transpeptidase site is typically blocked2 By using PBP2a for cross-linking while the native PBPs are inactive, MRSA effectively "bypasses" inhibition4. However, more recent research hasdemonstrated that this resistance can be overcome by focusing on the . Ceftaroline and other antibiotics bind to the allosteric domain first, opening the TP site long enough for the medication to reach the catalytic serine. Our understanding of how to overcome PBP2a-mediated resistance has significantly changed as a result of this "two-step" inhibitory process Other strategies include the use of combination treatments, like ampicillin with substances derived from plants, which seem to reduce resistance by changing conformational dynamics. All of these results demonstrate how antibiotic design is directly influenced by structural knowledge.

VI. References

1. Ambade, S. S., Gupta, V. K., Bhole, R. P., Khedekar, P. B., & Chikhale, R. V. (2023). A review on five and six-membered heterocyclic compounds targeting the penicillin-binding protein 2 (PBP2A) of Methicillin-resistant Staphylococcus aureus (MRSA). Molecules, 28(20), 7008.

2. Fisher, J. F., Meroueh, S. O., & Mobashery, S. (2005). Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. Chemical reviews, 105(2), 395-424.

3. Otero, L. H., Rojas-Altuve, A., Llarrull, L. I., Carrasco-López, C., Kumarasiri, M., Lastochkin, E., ... & Hermoso, J. A. (2013). How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proceedings of the National Academy of Sciences, 110(42), 16808-16813.

4. Pinho, M. G., Filipe, S. R., de Lencastre, H., & Tomasz, A. (2001). Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. Journal of bacteriology, 183(22), 6525-6531.

5. Santiago, C., Pang, E. L., Lim, K. H., Loh, H. S., & Ting, K. N. (2015). Inhibition of penicillin-binding protein 2a (PBP2a) in methicillin resistant Staphylococcus aureus (MRSA) by combination of ampicillin and a bioactive fraction from Duabanga grandiflora. BMC complementary and alternative medicine, 15(1), 178.

Back to Top